Azithromycin—Spectrum of Activity, Pharmacokinetics, and Clinical Applications
- 6 May 1992
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 12 (3) , 161-173
- https://doi.org/10.1002/j.1875-9114.1992.tb04504.x
Abstract
Azithromycin is an azalide antimicrobial agent. Structurally related to the macrolide antibiotic erythromycin, its mechanism of activity (similar to erythromycin) is interference with bacterial protein synthesis by binding to the 50S component of the 70S ribosomal subunit. Although slightly less potent than erythromycin against gram-positive organisms, azithromycin demonstrates superior activity in vitro against a wide variety of gram-negative bacilli, including Haemophilus influenzae. Absorption is approximately 37% after a 500-mg oral dose. The large volume of distribution (23 L/kg) and low peak serum level (0.4 μg/ml) are consistent with data demonstrating extensive tissue distribution and intracellular accumulation. Metabolism is predominantly hepatic (to inactive metabolites), with biliary excretion a major pathway of elimination. Drug elimination is biphasic, with a terminal half-life of up to 5 days. Published trials have examined the efficacy and safety of azithromycin in the treatment of adults with upper and lower respiratory tract infections, skin and skin structure infections, streptococcal pharyngitis, and sexually transmitted diseases. Many used a 5-day course of 250 mg once daily, supplemented with a 250-mg dose on the first day of therapy. Selected trials in sexually transmitted diseases examined single 1-g doses. Promising results also were obtained with oral daily doses of 500 mg. in patients with human immunoviral infection who also had Mycobacterium avium complex infection and in animals with toxoplasmosis. Adverse reactions are primarily gastrointestinal (nausea, diarrhea, abdominal pain), with minimal laboratory abnormalities reported. Gastrointestinal tolerance is better than that of erythromycin. Drug interactions have not been observed to date, although coadministration of azithromycin with a large meal may reduce absorption by up to 50%.Keywords
This publication has 66 references indexed in Scilit:
- An open study to compare the pharmacokinetics, safety and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteersEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Introduction: Revolutionary changes in the macrolide and azalide antibioticsThe American Journal of Medicine, 1991
- The Effects of an Antacid or Cimetidine on the Serum Concentrations of AzithromycinThe Journal of Clinical Pharmacology, 1991
- Drug resistance in Giardia intestinalisInternational Journal for Parasitology, 1990
- Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamineJournal of Antimicrobial Chemotherapy, 1990
- Activity of new macrolides againstBordetella pertussis andBordetella parapertussisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Comparative antimicrobial activity of the new macrolides againstBorrelia burgdorferiEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Clinical Pharmacokinetic Properties of the Macrolide AntibioticsClinical Pharmacokinetics, 1989
- Comparative in vitro activity of the new oral macrolide azithromycinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988